SpringerLink
Log in

Phase II study of pemetrexed plus oxaliplatin for platinum-resistant advanced or metastatic non-small cell lung cancer patients

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

This study was designed to evaluate the efficacy of combination treatment of pemetrexed plus oxaliplatin as second-line treatment in advanced/metastatic non-small cell lung cancer (NSCLC) patients who have failed first-line platinum-based chemotherapy, assuming that oxaliplatin can overcome the resistance to a platinum agent and translate into better outcome. Patients having shown progressive disease on first-line platinum-based chemotherapy received pemetrexed (500 mg/m2) and oxaliplatin (120 mg/m2) every 21 days till disease progression, unacceptable toxicity, or patient’s refusal. As a result, 15 patients (10 squamous cell carcinoma, 15 men, and 12 ECOG of 1) participated in this study. Disappointedly, there was no response and 2 stable diseases, and therefore, as per protocol, we stopped the study early. Median survival time was 6.1 months. In conclusion, treatment with oxaliplatin and pemetrexed did not show activity in this population as second-line treatment. Further investigation could not be recommended or should be made in more selected population, such as, non-squamous NSCLC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998;4:1087–100.

    PubMed  CAS  Google Scholar 

  2. Barlesi F, Jacot W, Astoul P, et al. Second-line treatment for advanced non-small cell lung cancer: a systemic review. Lung Cancer. 2006;51:159–72.

    Article  PubMed  Google Scholar 

  3. Azzoli CG, Giaccone G, Temin S. American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Oncol Pract. 2010;6:39–43.

    Article  PubMed  Google Scholar 

  4. Rusthoven J, Eisenhauer E, Butts C, et al. Multitargeted antifolate, LY231514, as first-line chemotherapy for patients with advanced nonsmall- cell lung cancer: a phase II study. J Clin Oncol. 1999;17:1194–9.

    PubMed  CAS  Google Scholar 

  5. Clarke SJ, Abratt R, Goedhals L, et al. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small cell lung cancer. Ann Oncol. 2002;13:737–41.

    Article  PubMed  CAS  Google Scholar 

  6. Manegold C, VonPawel J, Pirker R, et al. Front-line treatment of advanced non-small cell lung cancer with MTA and cisplatin: a multicenter phase II trial. Ann Oncol. 2000;11:435–40.

    Article  PubMed  CAS  Google Scholar 

  7. Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced non-small cell lung carcinoma. Cancer. 2001;92:595–600.

    Article  PubMed  CAS  Google Scholar 

  8. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–97.

    Article  PubMed  CAS  Google Scholar 

  9. Raymond E, Chaney S, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998;9:1053–71.

    Article  PubMed  CAS  Google Scholar 

  10. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute’s anticancer drug screen panel. Biochem Pharmacol. 1996;2:1855–65.

    Article  Google Scholar 

  11. Piccart MJ, Green JA, Lacave AJ, et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European organization for research and treatment of cancer gynecology group. J Clin Oncol. 2000;18:1193–202.

    PubMed  CAS  Google Scholar 

  12. Soulie P, Garrino C, Bensmaine MA, et al. Antitumor activity of oxaliplatin/cisplatin based combination therapy in cisplatin-refractory germ cell cancer patients. J Cancer Res Clin Oncol. 1999;125:707–11.

    Article  PubMed  CAS  Google Scholar 

  13. Misset JL, Gamelin E, Campone M, et al. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors. Ann Oncol. 2004;15:1123–9.

    Article  PubMed  CAS  Google Scholar 

  14. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–51.

    Article  PubMed  CAS  Google Scholar 

  15. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist. 2009;14:253–63.

    Article  PubMed  CAS  Google Scholar 

  16. Adjei AA, Mandrekar SJ, Dy GK, et al. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non–small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol. 2010;28:614–9.

    Article  PubMed  CAS  Google Scholar 

  17. Heist RS, Fidias P, Huberman M, et al. A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer. J Thorac Oncol. 2008;3(10):1153–8.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Oxaliplatin (Oxalitin®) was kindly provided by Boryung Pharmaceutical (Seoul, Korea).

Conflict of interest

None declared.

Author information

Authors and Affiliations

  1. Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 388-1 Pungnap-2 dong, Songpa-gu, 138736, Seoul, Korea

    Dae Ho Lee, Chang-Min Choi, Sang-We Kim, Cheolwon Suh & Jung-Shin Lee

Authors
  1. Dae Ho Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chang-Min Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sang-We Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cheolwon Suh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jung-Shin Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dae Ho Lee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, D.H., Choi, CM., Kim, SW. et al. Phase II study of pemetrexed plus oxaliplatin for platinum-resistant advanced or metastatic non-small cell lung cancer patients. Med Oncol 29, 640–643 (2012). https://doi.org/10.1007/s12032-011-9944-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-9944-6

Keywords

Search

Navigation